Format
Sort by
Items per page

Send to

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 62

1.

Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system.

Sriprasert I, Stanczyk FZ, Archer DF.

Expert Opin Pharmacother. 2015;16(12):1901-9. doi: 10.1517/14656566.2015.1056733.

PMID:
26194214
2.

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.

Song IH, Borland J, Chen S, Wajima T, Peppercorn AF, Piscitelli SC.

Ann Pharmacother. 2015 Jul;49(7):784-9. doi: 10.1177/1060028015580637.

3.

Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: a prospective study.

Hernandez-Juarez J, Garcia-Latorre EA, Moreno-Hernandez M, Moran-Perez JF, Rodriguez-Escobedo MA, Cogque-Hernandez G, Julián-Nacer R, Hernandez-Giron X, Palafox-Gomez R, Isordia-Salas I, Majluf-Cruz A.

Reprod Health. 2014 Apr 26;11:33. doi: 10.1186/1742-4755-11-33.

4.

Antimüllerian hormone levels decrease in women using combined contraception independently of administration route.

Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS.

Fertil Steril. 2013 Apr;99(5):1305-10. doi: 10.1016/j.fertnstert.2012.11.034.

PMID:
23260855
5.

Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses.

Lindberg M, Foldemo A, Josefsson A, Wiréhn AB.

Eur J Contracept Reprod Health Care. 2012 Apr;17(2):106-18. doi: 10.3109/13625187.2012.658925.

PMID:
22385398
6.

Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.

Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):473-82. doi: 10.1097/QAI.0b013e3181eb5ff5.

7.

Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study.

Massaro M, Di Carlo C, Gargano V, Formisano C, Bifulco G, Nappi C.

Contraception. 2010 Mar;81(3):209-14. doi: 10.1016/j.contraception.2009.09.011.

PMID:
20159176
8.

Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy.

Crosignani PG, Nappi C, Ronsini S, Bruni V, Marelli S, Sonnino D; Italian EVRA Contrast Study Group..

BMC Womens Health. 2009 Jun 30;9:18. doi: 10.1186/1472-6874-9-18.

9.

Determination of norelgestromin in rabbit plasma by LC-MS/MS and its application to the pharmacokinetic study of ORTHO EVRA.

Liu X, Ding C, Ge Q, Zhi X, Zhou Z.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):311-5. doi: 10.1016/j.jchromb.2008.11.034.

PMID:
19097950
10.

Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.

Schwartz JI, Dunbar S, Yuan J, Li S, Miller DL, Rosko K, Johnson-Levonas AO, Lasseter KC, Wagner JA.

J Clin Pharmacol. 2009 Jan;49(1):72-9. doi: 10.1177/0091270008325930.

PMID:
18936284
11.

Effect of the ethinylestradiol/norelgestromin contraceptive patch on body composition. Results of bioelectrical impedance analysis in a population of Italian women.

Piccoli A, Crosignani P, Nappi C, Ronsini S, Bruni V, Marelli S; Italian EVRA Contrast Study Group..

Nutr J. 2008 Aug 26;7:21. doi: 10.1186/1475-2891-7-21.

12.

A clinical study of transdermal contraceptive patch in Thai adolescence women.

Piyasirisilp R, Taneepanichskul S.

J Med Assoc Thai. 2008 Feb;91(2):137-41.

PMID:
18389975
13.

Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial.

Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S, Cushman M.

Obstet Gynecol. 2008 Feb;111(2 Pt 1):278-84. doi: 10.1097/AOG.0b013e3181626d1b.

PMID:
18238963
14.

Oral and transdermal hormonal contraception in women after kidney transplantation.

Pietrzak B, Bobrowska K, Jabiry-Zieniewicz Z, Kaminski P, Wielgos M, Pazik J, Durlik M.

Transplant Proc. 2007 Nov;39(9):2759-62.

PMID:
18021980
15.

A clinical study of transdermal contraceptive patch in Thai women.

Suwanmalee O, Taneepanichskul S.

J Med Assoc Thai. 2006 Oct;89 Suppl 4:S1-4.

PMID:
17726805
16.

Norelgestromin/ethinyl estradiol transdermal system.

Taneepanichskul S.

J Med Assoc Thai. 2005 Oct;88 Suppl 2:S82-4. Review. Retraction in: J Med Assoc Thai. 2010 Jul;93(7):873.

PMID:
17722322
17.

Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.

Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, Leung AT.

J Clin Pharmacol. 2007 Apr;47(4):497-509.

PMID:
17389559
18.

Performance of contraceptive patch compared with oral contraceptive pill in a high-risk population.

LaGuardia KD.

Obstet Gynecol. 2006 Dec;108(6):1553-4. No abstract available.

PMID:
17138794
19.

Hormonal contraception: recent advances.

Szarewski A.

J Fam Health Care. 2006;16(2):35-6. Review. No abstract available.

PMID:
16715750
20.

[Safety evaluation of a transdermal contraceptive system with an oral contraceptive].

Radowicki S, Skórzewska K, Szlendak K.

Ginekol Pol. 2005 Nov;76(11):884-9. Polish.

PMID:
16566363

Supplemental Content

Support Center